Compare LMFA & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMFA | VIVS |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | 19 | 9 |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 4.9M |
| IPO Year | 2015 | N/A |
| Metric | LMFA | VIVS |
|---|---|---|
| Price | $0.26 | $1.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 390.8K | 59.3K |
| Earning Date | 03-27-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,999,648.00 | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | $22.58 | $15.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.29 | $1.42 |
| 52 Week High | $5.14 | $5.30 |
| Indicator | LMFA | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 31.48 | 30.04 |
| Support Level | N/A | N/A |
| Resistance Level | $0.44 | $2.11 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 7.48 | 0.18 |
LM Funding America Inc is a financial services company. The company provides funding to nonprofit community associations located in the state of Florida and to nonprofit community associations in the states of Washington and Colorado. Its products include Original Product and New Neighbor Guaranty. Its original product offering consists of providing funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It currently has two lines of business recently commenced cryptocurrency mining business and historical specialty finance business. The Company has two operating segments: Specialty Finance and Mining Operations, which generate the majority of its revenue.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.